sofidexFor patientsAre you a clinician? Clinical site

Health Library  ›  News  ›  Health notices · Monday 2 November

Updates ·

Health notices · Monday 2 November

3 notices from the agencies today, in plain words, each with the original linked.

About 1 minute to readNoticePublished November 2026

PDF
a plain paper envelope and an unopened cardboard box on a table

FDA approval for dapagliflozin and metformin extended-release tablets

Food and Drug Administration (FDA) · Approval

If you have type 2 diabetes, the FDA has approved dapagliflozin and metformin HCl extended-release tablets as an add-on to diet and exercise to improve blood sugar control.

The tablet combines dapagliflozin (an SGLT2 inhibitor) and metformin (a biguanide). In some adults, dapagliflozin also helps reduce risks such as sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.

eGFR is a measure of kidney function. This product is limited to people with type 2 diabetes, and it is not recommended for type 1 diabetes or certain kidney-related situations described in the label.

Read the original notice

CDC highlights driver fatigue risk and ways to reduce it

Centers for Disease Control and Prevention (CDC) · Guidance

If you drive for work, CDC/National Institute for Occupational Safety and Health (NIOSH) notes that driver fatigue—caused by too little sleep, long hours, shift work, stress, sleep disorders, or drowsy medications—can reduce your ability to drive safely.

CDC/NIOSH says employers can use a fatigue risk management system (FRMS) and train workers to reduce the chain of events that can lead to crashes.

If you feel fatigued while driving, CDC/NIOSH advises you to pull over, drink a cup of coffee, and take a 15–30 minute nap before continuing; report fatigue and seek screening if it persists after adequate sleep.

What to do

  • If you feel fatigued while driving: pull over, drink a cup of coffee, and take a 15-30 minute nap before continuing.

Read the original notice

FDA approval of VEVYE (cyclosporine) for dry eye symptoms

FDA · Approval

If you have dry eye disease, the FDA has approved VEVYE (cyclosporine) ophthalmic solution (eye drops). It is for the signs and symptoms of dry eye disease.

Cyclopsorine is a calcineurin inhibitor immunosuppressant. In this medicine, that means it works in the eye to help relieve the discomfort and other symptoms of dry eye.

Read the original notice